What is a stock summary page? Click here for an overview.
Business Description
Bicycle Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US0887861088
Share Class Description:
BCYC: ADRDescription
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 92.65 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.87 | |||||
| Beneish M-Score | -1.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.1 | |||||
| 3-Year EBITDA Growth Rate | -3.5 | |||||
| 3-Year EPS without NRI Growth Rate | -2.5 | |||||
| 3-Year FCF Growth Rate | -62 | |||||
| 3-Year Book Growth Rate | -0.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -8.07 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 35.38 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.77 | |||||
| 9-Day RSI | 30.93 | |||||
| 14-Day RSI | 31.67 | |||||
| 3-1 Month Momentum % | -23.42 | |||||
| 6-1 Month Momentum % | -52.33 | |||||
| 12-1 Month Momentum % | -55.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.81 | |||||
| Quick Ratio | 13.81 | |||||
| Cash Ratio | 13.08 | |||||
| Days Sales Outstanding | 2.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -32.7 | |||||
| Shareholder Yield % | -81.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -592.92 | |||||
| Net Margin % | -479.18 | |||||
| FCF Margin % | -470.47 | |||||
| ROE % | -26.21 | |||||
| ROA % | -20.35 | |||||
| ROIC % | -280.07 | |||||
| 3-Year ROIIC % | -1310.88 | |||||
| ROC (Joel Greenblatt) % | -762.58 | |||||
| ROCE % | -22.4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.34 | |||||
| PB Ratio | 0.78 | |||||
| Price-to-Tangible-Book | 0.78 | |||||
| EV-to-EBIT | 1.35 | |||||
| EV-to-EBITDA | 1.41 | |||||
| EV-to-Revenue | -6.61 | |||||
| EV-to-Forward-Revenue | 0.23 | |||||
| EV-to-FCF | 1.29 | |||||
| Price-to-GF-Value | 0.43 | |||||
| Price-to-Projected-FCF | 59.87 | |||||
| Price-to-Net-Current-Asset-Value | 0.81 | |||||
| Price-to-Net-Cash | 0.87 | |||||
| Earnings Yield (Greenblatt) % | 74.07 | |||||
| FCF Yield % | -26.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCYC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bicycle Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 35.275 | ||
| EPS (TTM) ($) | -2.88 | ||
| Beta | 1.66 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 44.41 | ||
| 14-Day RSI | 31.67 | ||
| 14-Day ATR ($) | 0.689953 | ||
| 20-Day SMA ($) | 10.1435 | ||
| 12-1 Month Momentum % | -55.87 | ||
| 52-Week Range ($) | 8.88 - 28.6701 | ||
| Shares Outstanding (Mil) | 69.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bicycle Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bicycle Therapeutics PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bicycle Therapeutics PLC Frequently Asked Questions
What is Bicycle Therapeutics PLC(BCYC)'s stock price today?
The current price of BCYC is $8.98. The 52 week high of BCYC is $28.67 and 52 week low is $8.88.
When is next earnings date of Bicycle Therapeutics PLC(BCYC)?
The next earnings date of Bicycle Therapeutics PLC(BCYC) is 2025-05-02 Est..
Does Bicycle Therapeutics PLC(BCYC) pay dividends? If so, how much?
Bicycle Therapeutics PLC(BCYC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers